Anti-MRSA β-lactams in development
Copyright policy )Anti-MRSA β-lactams in development
Ceftobiprole medocaril, the most advanced of the anti-MRSA (methicillin-resistant Staphylococcus aureus) beta-lactams in clinical development, has recently completed its first Phase III clinical trial, and has demonstrated non-inferiority to vancomycin. Phase II clinical trials have been initiated with PPI0903, which is, like ceftobiprole medocaril, an injectable pro-drug of a broad-spectrum cephalosporin with anti-MRSA activity, and with RO4908643, a carbapenem with more modest activity against MRSA.
Staphylococcus aureus, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Drug Design, Methicillin Resistance, beta-Lactams, Anti-Bacterial Agents, Cephalosporins
Staphylococcus aureus, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Drug Design, Methicillin Resistance, beta-Lactams, Anti-Bacterial Agents, Cephalosporins
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).54 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!